The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.
The company increased its 2019 revenue forecast and shrunk its net loss significantly in its push to become cash flow breakeven by the end of the year.
The firm's clinical service revenues were up also 51 percent, and it also announced it has signed a contract with insurer Humana.
While total revenues were up less than 1 percent, the Diagnostics division grew revenues 5 percent. Discovery & Analytical Solutions dipped 2 percent.
The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.
The company said it has faced competitive pressures in its diagnostics business, partially offset by organizational streamlining efforts it initiated last year.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
The company said its testing services revenues for the quarter rose nearly 120 percent year over year.
The firm will expand on its MSI assay for use in immunotherapy while developing liquid biopsy assays to monitor patients post therapy and for recurrence.
The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.